Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial

Ähnliche Einträge

• Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study
  von: Bousser, Marie-Germaine, et al.
  Veröffentlicht: (2009)
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
  Veröffentlicht: (2014)
• Rationale and design of the prevention of cerebrovascular and cardiovascular events of ischemic origin with Terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study
  von: Hennerici, Michael G.
  Veröffentlicht: (2009)
• Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial
  Veröffentlicht: (2008)
• Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies
  von: Wilson, Duncan, et al.
  Veröffentlicht: (2019)